Article

Press Release

Study Finds Large Gap in Breast Cancer Treatment Recommendations for Patients Aged 70 vs 69

Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.

Suzanne B. Evans, MD, MPH, FASTRO

Suzanne B. Evans, MD, MPH, FASTRO

Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.

Radiation therapy often is given after breast-conserving surgery to help prevent a patient’s cancer from returning. While post-surgical radiation may be omitted for certain patients with early-stage breast cancer – including older patients with lower-risk disease – it remains standard-of-care for patients with a higher risk of cancer recurrence. In this analysis of nationwide data, however, researchers found that patients in this higher-risk subset who were age 70 at the time of diagnosis “were nearly twice as likely to be passed over for radiation1” as those age 69.

Patients diagnosed at age 70 were 53% less likely to be recommended post-operative radiation and 39% less likely to receive it, compared to patients age 69. There were no similar gaps between other year-over-year age groups (68 vs 69, 70 vs 71, etc.). The study, which is published in the International Journal of Radiation Oncology•Biology•Physics, is among “the first to demonstrate an age cutoff heuristic in oncology.”

“Our findings suggest that cognitive heuristics, or ‘rules of thumb,’ play a greater role in physician decision-making than we previously realized. It’s important that we center individual patients, with the unique characteristics of their cancer, as well as their individual preferences, in treatment decisions,” said Suzanne B. Evans, MD, MPH, FASTRO, senior author of the study and a professor of therapeutic radiology at Yale Cancer Center.

“While we would expect recommendations for this treatment to decline gradually as expected lifespan shortens, there seems to be a steep cliff when a patient moves from their 60s to their 70s. In breast oncology, physicians seem to anchor on a patient entering their 70s as a signal to de-escalate care, even in situations where evidence does not support this practice,” said Wesley J. Talcott, MD, MBA, lead author of the study and a radiation oncologist with Northwell Health. “Our study indicates that physicians should be mindful of how we factor age into treatment decisions and adopt a more nuanced approach, extending beyond defining patients as simply ’young’ or ’elderly.’”

Related Videos
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
David Rimm, MD, PhD
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
David Rimm, MD, PhD
A panel of 3 experts on nasopharyngeal carcinoma
David Rimm, MD, PhD
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma